You are here

  • Home
  • Archive
  • Volume 82, Issue 6
  • Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hocevar et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hocevar et al
  1. Philipp Gauckler1,
  2. Erica L Bettac2,
  3. Andreas Kronbichler1
  1. 1 Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria
  2. 2 Department of Psychology, Washington State University - Vancouver, Vancouver, Washington, USA
  1. Correspondence to Dr Andreas Kronbichler, Internal Medicine IV, Nephrology and Hypertension, Innsbruck Medical University, Innsbruck 6020, Austria; andreas.kronbichler{at}i-med.ac.at

http://dx.doi.org/10.1136/annrheumdis-2021-220324

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In our previous report on antineutrophil cytoplasm antibodies (ANCA)-associated vasculitides (AAV) during the current COVID-19 pandemic, we described our observation of both an incidence-shift with a post-lockdown clustering and an increased incidence rate of AAV diagnoses between February and August 2020 compared with previous years.1

    In correspondence to our article, Hocevar et al report how COVID-19 pandemic affected management of patients with vasculitides at their centre. The in-depth analysis examined symptom duration (ie, time eclipsed to final diagnosis), disease activity/severity and seasonal changes of patients presenting with giant cell arteritis, and IgA vasculitis and AAV during 2020 and in the previous decade. No significant differences were found in incidence rates or indications for deferrals; that is, symptoms were experienced for a longer length of time before a diagnosis was made or a more severe presentation occurred.2

    As the COVID-19 pandemic remains ongoing, six patients with AAV treated at …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors All authors have contributed in design, and writing of the Correspondence.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles